Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine in adolescents with schizophrenia
NCT00090324Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of quetiapine in schizophrenia (3 arms), sponsored by AstraZeneca. Primary endpoint: Positive and Negative Syndrome Scale total score at 42 days. Started Sep 2004; status: completed.
02
Drugs
quetiapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00090324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090324.